Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 2/2015

01.02.2015 | Kidney Diseases (G Ciancio, Section Editor)

Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature

verfasst von: Daniele Minardi, Luigi Quaresima, Matteo Santoni, Maristella Bianconi, Mario Scartozzi, Stefano Cascinu, Giovanni Muzzonigro

Erschienen in: Current Urology Reports | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Sunitinib is an orally available inhibitor of multiple tyrosine-kinase receptors approved for the treatment of advanced clear-cell renal cell carcinoma (ccRCC), a disease which has habitually had a very poor patient survival rate. Although it has become the most widely used drug for this disease, it remains not completely clear the best treatment strategy with these agent. The aim of this review is to highlight the most recent and interesting aspects of the research on treatment of advanced ccRCC with sunitinib and eventually determine alternative treatment schedule to reduce the incidence of side effects; we also wanted to review recent biomarkers able to predict response to therapy and also to point out the mechanism of acquired resistance to this drug.
Literatur
1.
2.
McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–41.CrossRefPubMed
3.
Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.CrossRefPubMed
4.
Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406.CrossRefPubMed
5.
Sweeney CJ, Chiorean EG, Verschraegen CF, et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol. 2010;28(29):4513–20.CrossRefPubMedCentralPubMed
6.
Yoon SH, Kim KH, Choi J, et al. Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. Cancer Res Treat. 2010;42(3):180–4.CrossRefPubMedCentralPubMed
7.
Motzer RJ, Rini BI, Bukowsky RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–24.CrossRefPubMed
8.
Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.CrossRefPubMedCentralPubMed
9.
Sato M, Nakai Y, Nakata W, et al. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to Sunitinib in renal cell carcinoma, and its level predicts patient outcome. PLoS ONE. 2013;8(9):e74313.CrossRefPubMedCentralPubMed
10.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.CrossRefPubMed
11.
Gore ME, Sczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10:757–63.CrossRefPubMed
12.
13.
Atkinson BJ, Kalra S, Wang X, Tannir NM, Jonasch E. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191:611–8.CrossRefPubMed
14.
Bjarnason GA, Khalil B, Hudson JM, Williams R, Milot LM, Atri M, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. 2014;32:480–7.CrossRefPubMed
15.
Neri B, Vannini A, Brugia M, Muto A, Rangan S, Rediti M, et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients. Int J Urol. 2013;20:478–83.CrossRefPubMed
16.
Kletas V, Cheng W, Kollmannsberger CK, Law De Lemos M, Man S. A population-based analysis of overall survival associated with sunitinib given as intermittent, continuous, or nonconventional individualized dosing regimens for metastatic renal cell carcinoma. J Clin Oncol. 2013;31:abstr e15541.
17.
Bracarda S, Iacovelli R, Rizzo M, Rossi M, Galli L, Procopio G, et al. Retrospective observational study of sunitinib administered on schedule 2/1 in patients with metastatic renal cell carcinoma (mRCC): the rainbow study. J Clin Oncol. 2014;32:abstr 471.CrossRef
18.
Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50:1084–9.CrossRefPubMed
19.
Kinsui H, Ueda T, Suzuki H, Isaka S, Sekita N, Komiya A, et al. Expression of thymidine phosphorylase in primary human renal cell carcinoma by ELISA method. Jpn J Cancer Res. 2002;93(3):340–5.CrossRefPubMed
20.
Takayama T, Mugiya S, Sugiyama T, Aoki T, Furuse H, Liu H, et al. High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma. Jpn J Clin Oncol. 2006;36(9):564–9.CrossRefPubMed
21.
Scartozzi M, Bianconi M, Falloppi L, Loretelli C, Bittoni A, Del Prete M, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 2013;108(5):1126–32.PubMedCentralPubMed
22.•
Minardi D, Lucarini G, Santoni M, Mazzucchelli R, Burattini L, Pistelli M, et al. VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res. 2013;33(11):5017–22. In this article, the authors correlate the expression of vascular endothelial growth factor to the response to sunitinib as the first-line treatment for metastatic ccRCC.PubMed
23.
Minardi D, Santoni M, Lucarini G, Mazzucchelli R, Burattini L, Conti A, et al. Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients. Urol Oncol. 2014;1439(14):00220–8. doi:10.​1016/​j.​urolonc.​2014.​06.​014.
24.
Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del Prete M, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 2013;108(5):1126–32.PubMedCentralPubMed
25.
Bianconi M, Scartozzi M, Faloppi L, Bittoni A, Maccaroni E, Giampieri R, et al. Angiogenetic pathway as a therapeutic target in renal cell carcinoma. Anal Quant Cytol Histol. 2012;34(1):15–22.PubMed
26.
Hamada I. A clinical study on tumor-associated monocyte lineage cells in renal cell carcinoma. Hinyokika Kiyo. 2002;48(4):213–20.PubMed
27.
Hamada I, Kato M, Yamasaki T, Iwabuchi K, Watanabe T, Yamada T, et al. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res. 2002;22(6C):4281–4.PubMed
28.
Patard JJ, Rioux-Leclercq N, Masson D, Zerrouki S, Jouan F, Collet N, et al. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer. 2009;101(8):1417–24.CrossRefPubMedCentralPubMed
29.
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005;11(10):3714–21.CrossRefPubMed
30.
Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123(2):395–400.CrossRefPubMedCentralPubMed
31.
Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98(4):756–62.CrossRefPubMed
32.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.CrossRefPubMed
33.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.CrossRefPubMed
34.
Mikami S, Mizumo R, Kosaka T, Saya H, Oya M, Okada Y. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer. 2014. doi:10.​1002/​ijc.​29137.
35.
Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2014;73:151–61.CrossRefPubMedCentralPubMed
36.
Garcia-Donas J, Leandro-Garcia LJ, Gonzalesdel Alba A, Morente M, Alemany I, Esteban E, et al. Prospective study assessing hypoxia-related proteins as a marker for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013;24(9):2409–14.CrossRefPubMed
37.
Kust D, Prpič M, Murgič J, Jazvič B, Jakšić B, Krilić D, et al. Hypothyroidism as a predictive clinical biomaker of better treatment response to sunitinib therapy. Anticancer Res. 2014;34(6):3177–84.PubMed
38.
Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, et al. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. Br J Cancer. 2013;109:332–241.CrossRefPubMedCentralPubMed
39.••
Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108:2470–7. Motzer et al. identified in this study the prognostic factors for PFS and OS in patients treated with sunitinib for metastatic renal cell carcinoma.CrossRefPubMedCentralPubMed
40.
Fujita T, Iwamura M, Ishii D, Tabata K-I, Matsumoto K, Yoshida K, et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol. 2012;19:908–13.CrossRefPubMed
41.
Dirican A, Kucukzeybek Y, Erten C, Somali I, Demir L, Can A, et al. Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev. 2013;14:2101–5.CrossRefPubMed
42.
Beuselinck B, Vano Y-A, Oudard S, Woler P, De Smet R, Depoorter L, et al. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 2014;114:81–9.CrossRefPubMed
43.
Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival, and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48(2):202–8.CrossRefPubMedCentralPubMed
44.••
Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, Gonzales del Alba A, Climent MA, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12:1143–50. In this study, the authors evaluated how the analysis of polymorphism of VEGF and VEGFR could help to select proper patients to be treated with sunitinib to improve treatment outcome. They also identified polymorphisms in VEGFR3 and CYP3A5*1 as responsible.CrossRefPubMed
45.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, et al. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib—a multicentric retrospective analysis. Acta Oncol. 2014;53:103–12.CrossRefPubMed
46.
Yang Y-Q, Chen J. Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients. Genet Mol Res. 2014;13(3):5011–7.CrossRefPubMed
47.
Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763–73.CrossRefPubMedCentralPubMed
48.
Keizman D, Huang P, Eisenberg MA, Pili R, Kim JJ, Antonarakis S, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer. 2011;47(13):1955–61.CrossRefPubMedCentralPubMed
49.
Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003;170(2 Pt 1):588–92.CrossRefPubMed
50.
Dorevic G, Matusan-Ilijas K, Babarovic E, Hadzisejdic I, Grahovac M, Grahovac B, et al. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2009;28:40.CrossRefPubMed
51.
Zhang N, Gong K, Yang XY, Xin DQ, Na YQ. Expression of hypoxia-inducible factor-1-alpha, hypoxia-inducible factor-2alpha and vascular endothelial growth factor in sporadic clear cell renal cell renal cell carcinoma and their significance in the pathogenesis thereof. Zhonghua Yi Xue Za Zhi. 2006;86(22):1526–9.PubMed
52.
Baldewijns MM, Thijssen VL, Van den Eynden GG, Van Laere SJ, Bluekens AM, Roskams T, et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer. 2007;96(12):1888–95.CrossRefPubMedCentralPubMed
53.
Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch. 2000;436(4):351–6.CrossRefPubMed
54.
Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, et al. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol. 2008;21(2):447–55.PubMed
55.
Toge H, Inagaki T, Kojimoto Y, Shinka T, Hara I. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol. 2009;16(10):801–7.CrossRefPubMed
56.
Zhang N, Gong K, Guo HF, Na X, Wu G, Yang XY, et al. Mutation of von Hippel-Lindau gene and expression of vascular endothelial growth factor in sporadic clear cell renal cell carcinoma and their relationships to angiogenesis. Zhonghua Yi Xue Za Zhi. 2004;84(19):1620–4.PubMed
57.
Kavantzas N, Paraskevakou H, Tseleni-Balafouta S, Aroni K, Athanassiades P, Agrogiannis G, et al. Association between microvessel density and histologic grade in renal cell carcinomas. Pathol Oncol Res. 2007;13(2):145–8.CrossRefPubMed
58.
Terstappen LW, Huang S, Safford M, Lansdorp PM, Loken MR. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34 + CD38-progenitor cells. Blood. 1991;77(6):1218–27.PubMed
59.
Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54(15):4233–7.PubMed
60.
Minardi D, Lucarini G, Mazzucchelli R, Milanese G, Natali D, Galosi AB, et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urol. 2005;174(4 Pt 1):1208–12.CrossRefPubMed
61.
Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009;115(10):2092–103.CrossRefPubMedCentralPubMed
62.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
63.
Bielecka ZF, Czarnecka AM, Solarek W, et al. Mechanism of acquired resistance to tyrosine kinase inhibitors in clear-cell renal-cell carcinoma (ccRCC). Curr Signal Transd T. 2013;8:219–28.CrossRef
64.
Buczec M, Escudier B, Bartnik E, et al. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient’s bed to molecular mechanisms. Biochim Biophys Acta. 2014;1845(1):31–41.
65.
Ravaud A, Digue L, Trufflandier N, et al. VEGFR TKI ‘resistance’ or transient clinical insensivity to VEGFR TKI in metastatic renal cell carcinoma. Ann Oncol. 2010;21(2):431–2.CrossRefPubMed
66.
Grunwald V, Weikert S, Seidel C, et al. Efficacy of Sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34(6):310–4.CrossRefPubMed
67.
68.
Harada K, Miyake H, Kusuda Y, et al. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int. 2012;110(1):E1131–7.CrossRefPubMed
69.
Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–64.CrossRefPubMed
70.
Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to angiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70(3):1063–71.CrossRefPubMedCentralPubMed
71.
Gabison EE, Hoang-Xuan T, Mauviel A, et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005;87:361–8.CrossRefPubMed
72.
Nabeshima K, Iwasaki H, Koga K, et al. EMMPRIN (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int. 2006;56:359–67.CrossRefPubMed
73.
Metadaten
Titel
Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature
verfasst von
Daniele Minardi
Luigi Quaresima
Matteo Santoni
Maristella Bianconi
Mario Scartozzi
Stefano Cascinu
Giovanni Muzzonigro
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Current Urology Reports / Ausgabe 2/2015
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-014-0478-2

Weitere Artikel der Ausgabe 2/2015

Current Urology Reports 2/2015 Zur Ausgabe

Female Urology (K Kobashi, Section Editor)

The Role of Information Technology (Apps) in FPMRS

Kidney Diseases (G Ciancio, Section Editor)

Nephron-Sparing Surgery in Renal Cell Carcinoma: Current Perspectives on Technical Issues

Kidney Diseases (G Ciancio, Section Editor)

Renal Cell Carcinoma in Young Patients: a Review of Recent Literature

Female Urology (K Kobashi, Section Editor)

Percutaneous Tibial Nerve Stimulation and Sacral Neuromodulation: an Update

Female Urology (K Kobashi, Section Editor)

The Future of Research in Female Pelvic Medicine

Kidney Diseases (G Ciancio, Section Editor)

Laparascopic Nephrectomy: Different Techniques and Approaches

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise